As global markets continue to react to political developments and economic indicators, U.S. stocks have been marching toward record highs, buoyed by optimism around softer tariffs and artificial intelligence investments. In this environment of cautious optimism, growth companies with high insider ownership can offer intriguing opportunities for investors, as they often signal confidence in the company's future prospects and alignment between management and shareholders' interests.
Name | Insider Ownership | Earnings Growth |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.2% |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
Propel Holdings (TSX:PRL) | 36.8% | 38.9% |
Pharma Mar (BME:PHM) | 11.9% | 55.1% |
Brightstar Resources (ASX:BTR) | 16.2% | 84.1% |
Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 135% |
Fulin Precision (SZSE:300432) | 13.6% | 71% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 119.4% |
Findi (ASX:FND) | 35.8% | 110.7% |
Click here to see the full list of 1465 stocks from our Fast Growing Companies With High Insider Ownership screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company that develops biological drugs for central nervous system disorders, with a market cap of SEK19.23 billion.
Operations: The company's revenue is derived from its biotechnology segment, amounting to SEK167.14 million.
Insider Ownership: 33.9%
Earnings Growth Forecast: 51.3% p.a.
BioArctic is poised for significant growth, with revenue expected to increase by 41.4% annually, outpacing the market. Despite a volatile share price and no substantial insider buying recently, it trades at 37.5% below fair value estimates. The company has secured a lucrative agreement with Bristol Myers Squibb for its PyroGlu-Ab antibody program, potentially earning up to US$1.25 billion in milestone payments alongside royalties, which could enhance profitability and support future growth initiatives.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: HMS Networks AB (publ) provides products that facilitate communication and information sharing for industrial equipment globally, with a market cap of SEK23.06 billion.
Operations: Revenue Segments (in millions of SEK): Wireless Communications Equipment: 3012.72
Insider Ownership: 12.6%
Earnings Growth Forecast: 41% p.a.
HMS Networks is set for robust growth, with earnings projected to rise 41% annually, surpassing the Swedish market. Revenue growth at 17.6% per year is also strong but below the high-growth threshold. Despite a recent decline in profit margins from 20.2% to 11.5%, insider activity shows more buying than selling recently, though not in large volumes. The stock trades slightly below fair value but carries a high level of debt that warrants attention.
Simply Wall St Growth Rating: ★★★★★★
Overview: APT Medical Inc. focuses on the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China with a market cap of CN¥35.92 billion.
Operations: The company's revenue is primarily derived from its medical products segment, totaling CN¥1.96 billion.
Insider Ownership: 22%
Earnings Growth Forecast: 28.8% p.a.
APT Medical is poised for substantial growth, with earnings expected to rise significantly, outpacing the Chinese market. Revenue is forecasted to grow at 29.1% annually, well above the market average of 13.4%. Despite no recent insider trading activity, the company's high-quality earnings and anticipated return on equity of 29.7% in three years highlight its strong financial health. Recent events include an upcoming shareholders meeting in January 2025 and a Q3 earnings call last November.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OM:BIOA B OM:HMS and SHSE:688617.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。